Boston Scientific Analyst Slashes Price Target On Disappointing 2026 Outlook

All NewsFebruary 5, 2026

Boston Scientific beats Q4 estimates but gives disappointing 2026 guidance, with slowing organic growth and lowered price target.

Latest Ratings for BSX

DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsOverweight Feb 2022Raymond JamesMaintainsStrong Buy Feb 2022SVB LeerinkMaintainsMarket Perform

View More Analyst Ratings for BSX

View the Latest Analyst Ratings

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent